The world at a glance
- Population
- 8.22 billion 2025
- Life expectancy at birth
- 73.5 years, 2024
- People aged 65 and over
- 10.4 % of people, 2025
- Health spending per person
- 1,317 US$ per person, 2023
- Doctors
- 1.86 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Global Companion Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$13.44 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $7.77 Bn | — | — |
| 2025 (base) | $8.62 Bn | +$854.7 Mn | — |
| 2026 (forecast) | $9.57 Bn | +$948.7 Mn | +11% |
| 2027 (forecast) | $10.63 Bn | +$1.05 Bn | +23.2% |
| 2028 (forecast) | $11.80 Bn | +$1.17 Bn | +36.8% |
| 2029 (forecast) | $13.09 Bn | +$1.30 Bn | +51.8% |
| 2030 (forecast) | $14.53 Bn | +$1.44 Bn | +68.5% |
| 2031 (forecast) | $16.13 Bn | +$1.60 Bn | +87% |
| 2032 (forecast) | $17.91 Bn | +$1.77 Bn | +107.6% |
| 2033 (forecast) | $19.88 Bn | +$1.97 Bn | +130.5% |
| 2034 (forecast) | $22.06 Bn | +$2.19 Bn | +155.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $8.62 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $22.06 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.0% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Technology, indication and end user (see all) |
| Key players | Roche Diagnostics, Agilent Technologies, Qiagen N.V., Thermo Fisher Scientific Inc., Illumina, Inc. (see all) |
| Regulator worldwide | IMDRFSource: International Medical Device Regulators Forum. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Companion diagnostics are tests that show whether a patient is likely to benefit from a specific medicine, often a cancer drug.
Key segments of the companion Diagnostics market include technology (Next-Generation Sequencing, PCR and Immunohistochemistry) and indication (Lung Cancer, Breast Cancer and Colorectal Cancer).
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the companion Diagnostics market.
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the companion Diagnostics market room to grow, especially in emerging markets.
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the companion Diagnostics market.
The companion Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
There is no single global regulator; the International Medical Device Regulators Forum (IMDRF) helps national regulators align their device rules.[1] WHO reports that 4.5 billion people were not fully covered by essential health services in 2021.[2]
[1] International Medical Device Regulators Forum. Checked 14 Nov 2026.
[2] World Health Organization, universal health coverage. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how companion Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Global.
What doctors and scientists are doing in Companion Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Global · 1 shared keyword
Global · 1 shared keyword
Global
Global
Global
Global
Pharmaceuticals · Global
Public Health · Global
Digital Health · Global
Healthcare Services · Global
Pharmaceuticals · Global
Pharmaceuticals · Global